MorphoSys AG: Corporate Calendar 2021
MorphoSys AG has announced its 2021 financial reporting dates, including the Year-End Results on March 15, 2021 and the first quarter results on May 5, 2021. The Half-Year Report is scheduled for July 28, 2021, while the Third Quarter Statement will be released on November 10, 2021. The Annual General Meeting will be held on May 19, 2021. Investors can access the full calendar on the corporate website. MorphoSys focuses on developing innovative therapies for serious diseases, notably cancer, and has a significant pipeline including Monjuvi and Tremfya.
- Scheduled financial reporting dates provide transparency for investors.
- MorphoSys has multiple significant product candidates in clinical development.
- No financial data or projections provided in the press release.
PLANEGG/MUNICH, GERMANY / ACCESSWIRE / December 17, 2020 / Please note MorphoSys's financial reporting dates for 2021 as follows:
Publication of Interim Statement / Report | Conference Call | |
Year-End Results 2020 | March 15, 2021 // 10 pm CET | March 16, 2021 // 2 pm CET |
First Quarter Interim Statement 2021 | May 5, 2021 // 10 pm CEST | May 6, 2021 // 2 pm CEST |
Half-Year Report 2021 | July 28, 2021 // 10 pm CEST | July 29, 2021 // 2 pm CEST |
Third Quarter Interim Statement 2021 | Nov. 10, 2021 // 10 pm CET | Nov. 11, 2021 // 2 pm CET |
Annual General Meeting | May 19, 2021 |
For a direct import of the dates to your calendar, please visit our corporate website: https://www.morphosys.com/media-and-investors/morphosys-events#company-calendar
With season's greetings and best wishes for the New Year:
www.morphosys.com/xmas-2020
About MorphoSys
MorphoSys (NASDAQ:MOR)(FSE:MOR) is a commercial-stage biopharmaceutical company dedicated to the discovery, development and commercialization of exceptional, innovative therapies for patients suffering from serious diseases. The focus is on cancer. Based on its leading expertise in antibody, protein and peptide technologies, MorphoSys, together with its partners, has developed and contributed to the development of more than 100 product candidates, of which 27 are currently in clinical development. In 2017, Tremfya(R), developed by Janssen Research & Development, LLC and marketed by Janssen Biotech, Inc., for the treatment of plaque psoriasis, became the first drug based on MorphoSys' antibody technology to receive regulatory approval. In July 2020, the U.S. Food and Drug Administration (FDA) granted accelerated approval of MorphoSys' proprietary product Monjuvi(R) (tafasitamab-cxix) in combination with lenalidomide in patients with a certain type of lymphoma.
Headquartered near Munich, Germany, the MorphoSys group, including the fully owned U.S. subsidiary MorphoSys US Inc., has ~500 employees. More information at www.morphosys.com or www.morphosys-us.com.
Monjuvi(R) is a registered trademark of MorphoSys AG.
Tremfya(R) is a registered trademark of Janssen Biotech, Inc.
MorphoSys Forward-Looking Statements
This communication contains certain forward-looking statements concerning the MorphoSys group of companies, including the expectations regarding Monjuvi's ability to treat patients with relapsed or refractory diffuse large B-cell lymphoma, the further clinical development of tafasitamab-cxix, including ongoing confirmatory trials, additional interactions with regulatory authorities and expectations regarding future regulatory filings and possible additional approvals for tafasitamab-cxix as well as the commercial performance of Monjuvi. The words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "would," "could," "potential," "possible," "hope" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve known and unknown risks and uncertainties, which might cause the actual results, financial condition and liquidity, performance or achievements of MorphoSys, or industry results, to be materially different from any historic or future results, financial conditions and liquidity, performance or achievements expressed or implied by such forward-looking statements. In addition, even if MorphoSys' results, performance, financial condition and liquidity, and the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. Among the factors that may result in differences are MorphoSys' expectations regarding risks and uncertainties related to the impact of the COVID-19 pandemic to MorphoSys' business, operations, strategy, goals and anticipated milestones, including its ongoing and planned research activities, ability to conduct ongoing and planned clinical trials, clinical supply of current or future drug candidates, commercial supply of current or future approved products, and launching, marketing and selling current or future approved products, the global collaboration and license agreement for tafasitamab, the further clinical development of tafasitamab, including ongoing confirmatory trials, and MorphoSys' ability to obtain and maintain requisite regulatory approvals and to enroll patients in its planned clinical trials, additional interactions with regulatory authorities and expectations regarding future regulatory filings and possible additional approvals for tafasitamab-cxix as well as the commercial performance of Monjuvi, MorphoSys' reliance on collaborations with third parties, estimating the commercial potential of its development programs and other risks indicated in the risk factors included in MorphoSys' Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. MorphoSys expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements, unless specifically required by law or regulation.
For more information, please contact:
MorphoSys AG
Investor Contacts:
Dr. Julia Neugebauer
Senior Director
Tel: +49 (0)89 / 899 27 179
julia.neugebauer@morphosys.com
Myles Clouston
Senior Director
Tel: +1 857-772-0240
myles.clouston@morphosys.com
Media Contacts:
Thomas Biegi
Vice President
Tel.: +49 (0)89 / 89927 26079
Thomas.Biegi@morphosys.com
Jeanette Bressi
Director, US Communications
Tel: +1 617-404-7816
jeanette.bressi@morphosys.com
SOURCE: MorphoSys AG via EQS Newswire
View source version on accesswire.com:
https://www.accesswire.com/621456/MorphoSys-AG-Corporate-Calendar-2021
FAQ
What are MorphoSys's financial reporting dates for 2021?
When is the Annual General Meeting for MorphoSys in 2021?
What does MorphoSys focus on in its business?
What is MorphoSys's stock symbol?
